Assessing Patient Reported Quality of Care and Safety in Mohs Surgery During the COVID-19 Pandemic

Main Article Content

Jesalyn Tate
Jennifer Wang
Shreya Patel
Rajiv Nijhawan
Divya Srivastava


Mohs surgery, COVID-19, Coronavirus, Patient reported outcomes


COVID-19 has greatly impacted patients’ ability to receive medical care. Early on during the pandemic, skin cancer diagnosis and treatment were often delayed due to fear of viral spread. In certain locales, executive orders have prevented physicians from performing procedures that were not immediately lifesaving. This study aims to assess patient-reported quality of care and sense of safety while receiving Mohs micrographic surgery (MMS) during the pandemic. The intent of this study is to identify patient-specific factors that influence concerns and feelings of safety, and thus guide future safety measures. A telephone survey was administered to assess patient concerns about treatment delay, feelings of safety, and satisfaction. A retrospective chart review was performed to collect demographics, comorbidities, tumor characteristics, etc. A total of 144 patients (102 male, 42 female; average 71.9 years old) completed the study. Overall, patients felt safe and satisfied, with 75.7% reporting 10/10 safety (average 9.5/10) and 84% reporting 10/10 satisfaction (average 9.7/10). Patients had more notable levels of concern regarding pandemic-related treatment delays (median 2/10), compared to the risk of contracting COVID during their visit (median 1/10). Concerns regarding treatment delay included an increase in cancer size, spread, pain, and scarring. This study demonstrates that high levels of patient feelings of safety and satisfaction can be obtained with MMS during the pandemic. As the pandemic continues, it is imperative that patients can receive high quality and timely care without compromising safety. Outpatient dermatologic surgery can continue without jeopardizing patients' overall feeling of safety and satisfaction.


1. Nicholson P, Ali FR, Patalay R, Craythorne E, Mallipeddi R. Patient perceptions of Mohs micrographic surgery during the COVID‐19 pandemic and lessons for the next outbreak. Clinical and Experimental Dermatology. 2021 Jan;46(1):179-80.

2. Miranda BH, Jica RCI, Pinto-Lopes R, et al. St Andrew's COVID-19 Surgery Safety (StACS) study: Skin cancer [published online ahead of print, 2021 Feb 19]. J Plast Surg Hand Surg. 2021;1-7.

3. Der Sarkissian SA, Kim L, Veness M, Yiasemides E, Sebaratnam DF. Recommendations on dermatologic surgery during the COVID-19 pandemic. J Am Acad Dermatol. 2020;83(1):e29-e30.

4. Yuan JT, Brian SI. Urgent safety considerations for dermatologic surgeons in the COVID-19 pandemic. Dermatology online journal. 2020;26(8).

5. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7-30.

6. Baumann BC, MacArthur KM, Brewer JD, et al. Management of primary skin cancer during a pandemic: Multidisciplinary recommendations. Cancer. 2020;126(17):3900-3906.

7. Tee MW, Stewart C, Aliessa S, et al. Dermatologic surgery during the COVID-19 pandemic: Experience of a large academic center. J Am Acad Dermatol. 2021;84(4):1094-1096.

8. Nicholson P, Ali FR, Mallipeddi R. Impact of COVID‐19 on Mohs micrographic surgery: UK‐wide survey and recommendations for practice. Clinical and experimental dermatology. 2020 Oct;45(7):901-2.